Tag: Galapagos

Gilead Sciences Announced EMA’s Marketing Application for Filgotinib

Gilead Sciences, Inc. and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with...

Gilead and Galapagos Signed Research and Development Collaboration

Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative p...

Evotec and Galapagos to Focus on Fibrosis

Evotec AG and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small molecule programme, currently in pre-cli...